Summary by Moomoo AI
On July 26, 2024, Bristol-Myers Squibb Company (BMS) released its financial results for the second quarter of 2024, showcasing a 9% increase in revenues to $12.2 billion, with an 11% rise when adjusted for foreign exchange impacts. The growth was primarily driven by the company's Growth Portfolio and the drug Eliquis. U.S. revenues saw a 13% increase, while international revenues experienced a slight decline due to foreign exchange impacts. GAAP EPS was reported at $0.83, with Non-GAAP EPS at $2.07, reflecting net impacts from acquired IPRD charges and licensing income. The company also highlighted the U.S. approval of Breyanzi for follicular lymphoma and mantle cell lymphoma, and the ongoing regulatory review of subcutaneous Nivolumab in the U.S. and E.U. Additionally, BMS raised...Show More
